A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive<sup>TM</sup>) for COVID-19 Patients

<div>Change in ordinal scale. (a) The ordinal scale of disease severity was compared between placebo and ImmuActive groups from screening to the end of study. (b) Days required to reduce the disease severity by one unit.</div>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive<sup>TM</sup>) for COVID-19 Patients 

Figure 2 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActiveTM) for COVID-19 Patients 